E12 148
[3]
Prekovic S, van Royen ME, Voet AR, et al. The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther 2016;15:1702 – 12.
[4]
Wyatt AW, Azad AA, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2016;2:1598 – 606.
[5]
Rijnders M, deWit R, Boormans JL, Lolkema MPJ, van der Veldt AAM. Systematic review of immune checkpoint inhibition in urological cancers. Eur Urol 2017;72:411 – 23.
[6] Wang B, Lo UG, Wu K, et al. Developing new targeting strategy for
androgen receptor variants in castration resistant prostate cancer.
Int J Cancer. In press.
http://dx.doi.org/10.1002/ijc.30893 .Marzia Del Re
a,
*
Elisa Biasco
b
Stefania Crucitta
a
Lisa Derosa
b,
y
Eleonora Ro
fi
a
Cinzia Orlandini
b
Mario Miccoli
c
Luca Galli
b
Alfredo Falcone
b
Guido W. Jenster
d
Ron H. van Schaik
e
Romano Danesi
a
a
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical
and Experimental Medicine, University of Pisa, Pisa, Italy
b
Medical Oncology Unit, Department of Translational Research and New
Technologies in Medicine, University of Pisa, Pisa, Italy
c
Department of Clinical and Experimental Medicine, University of Pisa, Pisa,
Italy
d
Department of Urology, Erasmus University Medical Center, Rotterdam, The
Netherlands
e
Department of Clinical Chemistry, Erasmus University Medical Center,
Rotterdam, The Netherlands
*Corresponding author. Clinical Pharmacology and Pharmacogenetics
Unit, Department of Clinical and Experimental Medicine, University of
Pisa, 55 Via Roma, Pisa 56126. Italy. Tel. +39 050 2218646.
E-mail address:
marzia.delre@gmail.com(M. Del Re).
y
Current af
fi
liation:
Medical Oncology, Institut Gustave Roussy, Villejuif, France.
July 26, 2017
E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) e 11
–
e 1 2
e12